AbbVie Inc. $ABBV Holdings Raised by CWA Asset Management Group LLC

CWA Asset Management Group LLC grew its stake in shares of AbbVie Inc. (NYSE:ABBV) by 39.4% during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 71,640 shares of the company’s stock after acquiring an additional 20,264 shares during the period. CWA Asset Management Group LLC’s holdings in AbbVie were worth $16,587,000 as of its most recent SEC filing.

A number of other hedge funds have also modified their holdings of ABBV. Marshall & Sullivan Inc. WA acquired a new position in AbbVie in the 2nd quarter worth about $25,000. Evolution Wealth Management Inc. bought a new position in AbbVie during the second quarter valued at approximately $26,000. Spurstone Advisory Services LLC acquired a new stake in AbbVie in the second quarter valued at approximately $28,000. Financial Gravity Companies Inc. bought a new stake in AbbVie in the second quarter worth approximately $36,000. Finally, Bear Mountain Capital Inc. grew its position in AbbVie by 480.6% in the second quarter. Bear Mountain Capital Inc. now owns 209 shares of the company’s stock worth $40,000 after acquiring an additional 173 shares in the last quarter. 70.23% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

ABBV has been the subject of several analyst reports. Morgan Stanley lifted their price objective on shares of AbbVie from $261.00 to $269.00 and gave the company an “overweight” rating in a research note on Friday, December 12th. HSBC raised AbbVie from a “hold” rating to a “buy” rating and boosted their price target for the stock from $225.00 to $265.00 in a research report on Wednesday, December 10th. Wells Fargo & Company upped their price target on AbbVie from $240.00 to $260.00 and gave the stock an “overweight” rating in a research note on Friday, September 12th. Berenberg Bank raised AbbVie from a “hold” rating to a “buy” rating and raised their price objective for the company from $170.00 to $270.00 in a research note on Wednesday, September 17th. Finally, Bank of America upped their target price on AbbVie from $220.00 to $251.00 and gave the stock a “neutral” rating in a research report on Friday, October 3rd. Three analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and eight have assigned a Hold rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $245.84.

AbbVie Stock Performance

NYSE ABBV opened at $229.26 on Monday. The stock has a 50-day simple moving average of $226.69 and a 200 day simple moving average of $214.14. AbbVie Inc. has a twelve month low of $164.39 and a twelve month high of $244.81. The stock has a market capitalization of $405.19 billion, a PE ratio of 173.68, a P/E/G ratio of 0.96 and a beta of 0.36.

AbbVie (NYSE:ABBV) last issued its quarterly earnings results on Friday, October 31st. The company reported $1.86 EPS for the quarter, topping the consensus estimate of $1.77 by $0.09. AbbVie had a return on equity of 3,216.47% and a net margin of 4.00%.The company had revenue of $15.78 billion for the quarter, compared to the consensus estimate of $15.58 billion. During the same period in the previous year, the business posted $3.00 EPS. The company’s revenue for the quarter was up 9.1% on a year-over-year basis. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. As a group, equities research analysts forecast that AbbVie Inc. will post 12.31 EPS for the current fiscal year.

AbbVie Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, February 17th. Shareholders of record on Friday, January 16th will be issued a $1.73 dividend. This is a boost from AbbVie’s previous quarterly dividend of $1.64. The ex-dividend date of this dividend is Friday, January 16th. This represents a $6.92 dividend on an annualized basis and a yield of 3.0%. AbbVie’s payout ratio is currently 496.97%.

AbbVie Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.